1379. Determination of the Arbekacin Exposure Required to Prevent Amplification of Resistant Subpopulations Using Patient Pharmacokinetics Simulated in a Hollow-Fiber Infection Model (HFIM)

BACKGROUND: ME1100 (arbekacin inhalational solution) is an aminoglycoside in clinical development for the treatment of patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively). Due to the increase in resistance of Staphylococcus aureus and Pseudomon...

Descripción completa

Detalles Bibliográficos
Autores principales: VanScoy, Brian D, Lakota, Elizabeth A, Bhavnani, Sujata M, Giesel, Greg, Carranco, Ana I, Nagira, Yu, Ouchi, Shohei, Kondo, Kenichiro, Ambrose, Paul G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252722/
http://dx.doi.org/10.1093/ofid/ofy210.1210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252722/
http://dx.doi.org/10.1093/ofid/ofy210.1210

Ejemplares similares